ARC520, REP9AC 等新药近况如何

zasxz

兄弟离开论坛好久了。今日回来发现大伙都在，不错不错。想了解下这些新药情况如何了？每天吃小药片的日子真是不是滋味。。

咬牙硬挺

希望留在下一个拐角处

咬牙硬挺

rep 9ac一直处于传言阶段好几年了，个人不看好它了，噱头！

crysalechain

很讨厌吃药，每天定点，就怕忘了

zgct

研究不出好的抗乙肝病毒药的原因？。。。。某三甲医院医生。。。。2010-07-18 08:40francis25 | 分类：传染科 | 浏览2025次
为什么美国那么多顶尖科学家，却研究不出好的抗乙肝病毒药？
再过10~20年都不会有突破性进展，只会有一种新抗病毒药替代另一种旧抗病毒药，.......现在就有突破性进展甚至灭绝乙肝病毒了，对利益集团有什么长远的好处？他们会那么傻？

x321

打打针吃吃药也有好的呀，心情不好的时候也知道科学治疗已经不停进步了，只是还买不到新药   

crysalechain

回复 x321 的帖子

心态不错

StephenW

回复 zasxz 的帖子

Replicor to Make Six Presentations at EASL 2015


NEW YORK, April 8, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B (HBV) and hepatitis D (HDV) patients, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted six abstracts for presentation at the EASL 2015 annual meeting to be held April 22-26, 2015 in Vienna, Austria.

Four presentations, one oral and three poster, disclose new clinical and mechanistic data on the activity of nucleic acid polymers (NAPs) against chronic hepatitis B infection:

·       HBV RNA dynamics in patients receiving combined REP 2139-Ca / immunotherapy, a retroactive analysis from the REP 102 Asian trial in patients with chronic hepatitis B infection (Abstract O114).

·       Serum cytokine dynamics in patients receiving combined REP 2139-Ca / immunotherapy, a retroactive analysis from the REP 102 Asian trial in patients with chronic hepatitis B infection (Abstract P0659).

·       Pre-clinical analysis of activity and liver PK of various next generation NAP candidates against HBV infection using the DHBV surrogate model (Abstract P0542).

·       Activity of NAP compounds against HBV in vitro in HepaRG cells and primary human hepatocytes (Abstract P0556).

Two late breaking presentations, one oral and one poster, disclose new clinical and mechanistic data on the activity of NAPs against chronic hepatitis B / hepatitis D co-infection:

·       Interim disclosure of data from the REP 301 trial assessing the safety and efficacy of REP 2139-Ca alone and in combination with Pegasys® in patients with chronic hepatitis B / hepatitis D co-infection (Abstract LO2).



·       Preliminary activity data of NAPs against HDV infection in vitro (Abstract LP26).

Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations.  For the 2015 EASL Meeting: https://ilc-congress.eu/.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com or follow us on Twitter @replicorinc.

StephenW

Replicor6个介绍在2015年EASL.
首4是旧的结果,
最后两个将是新的.


纽约，2015年4月8日 - Replicor公司，靶向治疗慢性乙型肝炎（HBV）和丁型肝炎一家私人持有的生物制药公司（HDV）的患者，今天宣布，欧洲协会为肝脏的研究（EASL）评选委员会已经接受了6文摘呈现在EASL 2015年年度会议在奥地利维也纳举行4月22日至26日，2015年。

四介绍，一次口服和三个海报，披露核酸聚合物（国家行动计划），针对慢性乙肝感染的活性新的临床和机械数据：

·在接受联合REP 2139钙/免疫疗法，从患者的慢性乙肝感染（摘要O114）的REP 102亚洲审判追溯分析患者的HBV RNA动态。

·在接受联合REP 2139钙/免疫疗法，从患者的慢性乙肝感染（摘要P0659）的REP 102亚洲审判追溯分析患者的血清细胞因子动态。

·各种下一代NAP考生对HBV感染使用DHBV代理模型（摘要P0542）的活性和肝PK前的临床分析。

·NAP化合物对HBV体外HepaRG细胞和初级人肝细胞（摘要P0556）的活动。

两个最新突破性介绍，一次口服和一张海报，披露对慢性乙型肝炎/丁型肝炎合并感染国家行动方案的活动的新的临床和机械数据：

·从REP 301试验评估REP的安全性和有效性中期披露的数据显示2139-CA单独和慢性乙型肝炎/丁型肝炎合并感染（摘要LO2）与Pegasys®组合。



·对HDV感染的国家行动方案，在体外（摘要LP26）的初步活动数据。

Replicor的演讲将可在该公司的网站在发布会www.replicor.com/science/conference-presentations结束。 2015年EASL会议：https://ilc-congress.eu/。

关于Replicor

Replicor是一家私人持有的生物制药公司，在治疗HBV和HDV的发展的最先进的动物和人类的临床数据。该公司致力于加快有效治疗的发展与患者HBV和HBV / HDV感染。有关Replicor更多信息，请访问我们的网站www.replicor.com或关注我们的微博@replicorinc。

crysalechain

期待